keyword
MENU ▼
Read by QxMD icon Read
search

nsclc brain radiotherapy

keyword
https://www.readbyqxmd.com/read/29464135/impact-of-cyberknife-radiosurgery-on-median-overall-survival-of-various-parameters-in-patients-with-1-12-brain-metastases
#1
Judith Murovic, Victoria Ding, Summer S Han, John R Adler, Steven D Chang
Introduction This study's objective is to assess various patient, tumor and imaging characteristics and to compare median overall survival (OS) of 150 patients with 1-12 brain metastases post-CyberKnife radiosurgery (CKRS) (Accuray, Sunnyvale, California) alone. Methods Charts of 150 patients, from 2009-2014, treated with only CKRS for brain metastases were reviewed retrospectively for patient, tumor, and imaging characteristics. Parameters included demographics, Eastern Cooperative Oncology Group (ECOG) performance scores, number and control of extracranial disease (ECD) sites, cause of death (COD), histology, tumor volume (TV), and post-CKRS whole brain radiotherapy (WBRT)...
December 8, 2017: Curēus
https://www.readbyqxmd.com/read/29454155/immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-nsclc-approaches-on-special-subgroups-and-unresolved-burning-questions
#2
REVIEW
J Remon, N Vilariño, N Reguart
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in locally advanced disease as maintenance after chemo-radiotherapy and currently several trials are also exploring its efficacy in earlier stages of the disease to evaluate whether these results could be extrapolated to the adjuvant setting...
February 8, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29435193/targeted-drugs-for-systemic-therapy-of-lung-cancer-with-brain-metastases
#3
REVIEW
Ya-Wen Sun, Jian Xu, Jun Zhou, Wen-Juan Liu
Brain metastases are very common in lung cancer patients. The condition of these patients is complicated and difficult to treat, and adverse reactions following treatment can affect the nervous system, which severely reduces quality of life. Lung cancers are categorized as small cell lung cancers and non-small cell lung cancers. Patients with brain metastasis of small cell lung cancers are generally treated with brain radiotherapy and systemic chemotherapy, but stage III/IV patients with brain metastasis of non-small cell lung cancers are generally not responsive to radiotherapy or chemotherapy...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29383686/expected%C3%A2-paradigm-shift-in-brain-metastases-therapy-immune-checkpoint-inhibitors
#4
REVIEW
Vishal Jindal, Sorab Gupta
Brain metastasis (BM) is one of the dreadful complications of malignancies. The prognosis after BM is extremely poor and life expectancy is meager. Currently, our treatment modalities are limited to radiotherapy and surgical resection, which also has poor outcomes and leads to various neurological deficits and affects the quality of life of patients. New treatment modality, i.e., immune checkpoint inhibitors, has brought revolution in management of melanoma, renal cancer, and non-small cell lung cancer (NSCLC)...
January 30, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29368144/predictive-and-prognostic-clinical-and-pathological-factors-of-nivolumab-efficacy-in-non-small-cell-lung-cancer-patients
#5
J Garde-Noguera, P Martín Martorell, M De Julián, J Perez Altozano, C Salvador Coloma, J García Sánchez, A Insa Molla, M Martín, X Mielgo Rubio, S Marin Liébana, A Blasco Cordellat, S Blasco Molla, R Gironés, D Marquez Medina, F Aparisi, M C Bas Cerda, S Macia Escalante, A Sánchez, O Juan Vidal
BACKGROUND: Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. PATIENTS AND METHODS: Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry...
January 24, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29365347/whole-brain-radiotherapy-for-the-treatment-of-newly-diagnosed-multiple-brain-metastases
#6
REVIEW
May N Tsao, Wei Xu, Rebecca Ks Wong, Nancy Lloyd, Normand Laperriere, Arjun Sahgal, Eileen Rakovitch, Edward Chow
BACKGROUND: This is an update to the review published in the Cochrane Library (2012, Issue 4).It is estimated that 20% to 40% of people with cancer will develop brain metastases during the course of their illness. The burden of brain metastases impacts quality and length of survival. OBJECTIVES: To assess the effectiveness and adverse effects of whole brain radiotherapy (WBRT) given alone or in combination with other therapies to adults with newly diagnosed multiple brain metastases...
January 25, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29363116/eml4-alk-fusion-variant-v3-is-a-high-risk-feature-conferring-accelerated-metastatic-spread-early-treatment-failure-and-worse-overall-survival-in-alk-nsclc
#7
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J Herth, Claus P Heussel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas
In order to identify anaplastic lymphoma kinase-driven non-small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require novel therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variants V1, V2, V3 as detected by next-generation sequencing (NGS) or RT-PCR (n=67). Progression under tyrosine kinase inhibitor (TKI) treatment was evaluated both according to Response Evaluation Criteria in Solid Tumors (RECIST) and by the need to change systemic therapy...
January 24, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29354805/current-progress-and-outcomes-of-clinical-trials-on-using-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-therapy-in-non-small-cell-lung-cancer-patients-with-brain-metastases
#8
Ling-Ling Kong, Lin-Lin Wang, Li-Gang Xing, Jin-Ming Yu
Non-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations in epidermal growth factor receptor ( EGFR ) have been recognized as a key predictor of therapeutic sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Using EGFR-TKI alone or in combination with standard treatments such as whole-brain radiotherapy and surgery has been an effective strategy for the management of brain metastasis...
December 2017: Chronic diseases and translational medicine
https://www.readbyqxmd.com/read/29344766/patient-reported-symptoms-before-palliative-radiotherapy-predict-survival-differences
#9
Carsten Nieder, Thomas A Kämpe, Adam Pawinski, Astrid Dalhaug
BACKGROUND: Widely used prognostic scores, e. g., for brain or bone metastases, are based on disease- and patient-related factors such as extent of metastases, age and performance status, which were available in the databases used to develop the scores. Few groups were able to include patient-reported symptoms. In our department, all patients were assessed with the Edmonton Symptom Assessment System (ESAS, a one-sheet questionnaire addressing 11 major symptoms and wellbeing on a numeric scale of 0-10) at the time of treatment planning since 2012...
January 17, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29340055/concurrent-brain-radiotherapy-and-egfr-tki-may-improve-intracranial-metastases-control-in-non-small-cell-lung-cancer-and-have-survival-benefit-in-patients-with-low-ds-gpa-score
#10
Yongmei Liu, Lei Deng, Xiaojuan Zhou, Youling Gong, Yong Xu, Lin Zhou, Jin Wan, Bingwen Zou, Yongsheng Wang, Jiang Zhu, Zhenyu Ding, Feng Peng, Meijuan Huang, Li Ren, Tim Lautenschlaeger, Feng-Ming Spring Kong, You Lu
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has intracranial activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain radiotherapy (RT) and appropriate patients who need early brain RT remains undetermined. This is a retrospective study of EGFR-mutant NSCLC patients with newly diagnosed brain metastases (BMs) before EGFR-TKI initiation. Intra-cranial progression free survival (IC-PFS) and overall survival (OS) were measured from the date of EGFR-TKI treatment...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29282442/impact-of-cyberknife-radiosurgery-on-overall-survival-and-various-parameters-of-patients-with-1-3-versus-%C3%A2-4-brain-metastases
#11
Judith Murovic, Victoria Ding, Summer S Han, John R Adler, Steven D Chang
Introduction This study's objective is to compare the overall survivals (OSs) and various parameters of patients with 1-3 versus ≥ 4 brain metastases post-CyberKnife radiosurgery (CKRS) (Accuray, Sunnyvale, California) alone. Methods Charts of 150 patients, from 2009-2014, treated with only CKRS for brain metastases were reviewed retrospectively for overall survival (OS) and patient, tumor, and imaging characteristics. Parameters included demographics, Eastern Cooperative Oncology Group (ECOG) performance scores, number and control of extracranial disease (ECD) sites, cause of death (COD), histology, tumor volume (TV), and post-CKRS whole brain radiotherapy (WBRT)...
October 24, 2017: Curēus
https://www.readbyqxmd.com/read/29277823/clinical-significance-of-pd-l1-expression-in-brain-metastases-from-non-small-cell-lung-cancer
#12
Shinkichi Takamori, Gouji Toyokawa, Isamu Okamoto, Kazuki Takada, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Nobutaka Mukae, Fumihiko Hirai, Tetsuzo Tagawa, Yoshinao Oda, Toru Iwaki, Koji Iihara, Yoichi Nakanishi, Yoshihiko Maehara
AIM: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of ≥5%...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29276848/survival-after-whole-brain-radiotherapy-for-brain-metastases-from-lung-cancer-and-breast-cancer-is-poor-in-6325-dutch-patients-treated-between-2000-and-2014
#13
Paul M Jeene, Kim C de Vries, Johanna G H van Nes, Johannes J M Kwakman, Gerda Wester, Tom Rozema, Pètra M Braam, Jaap D Zindler, Peter Koper, Joost J Nuyttens, Hanneke A Vos-Westerman, Ilona Schmeets, Charles G H J Niël, Stefan Hutschemaekers, Yvette M van der Linden, Joost J C Verhoeff, Lukas J A Stalpers
BACKGROUND: Whole brain radiotherapy (WBRT) is considered standard of care for patients with multiple brain metastases or unfit for radical treatment modalities. Recent studies raised discussion about the expected survival after WBRT. Therefore, we analysed survival after WBRT for brain metastases 'in daily practice' in a large nationwide multicentre retrospective cohort. METHODS: Between 2000 and 2014, 6325 patients had WBRT (20 Gy in 4 Gy fractions) for brain metastases from non-small cell lung cancer (NSCLC; 4363 patients) or breast cancer (BC; 1962 patients); patients were treated in 15 out of 21 Dutch radiotherapy centres...
December 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29245278/tonsillar-metastasis-of-nonsmall-cell-lung-cancer-with-g719s-mutation-in-exon-18-a-case-report
#14
Yimin Wu, Zhouyu Zhu, Yongyuan Chen, Ying Chai
RATIONALE: Lung cancer has the highest mortality of all malignant tumors and is becoming the leading cause of death in China. Surgical resection is the best treatment for early non-small-cell lung carcinoma. But postoperative tumor recurrence is very common. Brain, bone and liver are the most common metastatic sites of lung cancer. PATIENT CONCERNS: A 59-year-old woman was admitted to our hospital finding a lung nodule in physical examination. No other obvious symptoms were obsessed in this patient...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29223987/radiosurgery-for-brain-metastases-changing-practice-patterns-and-disparities-in-the-united-states
#15
Benjamin H Kann, Henry S Park, Skyler B Johnson, Veronica L Chiang, James B Yu
Background: Management of brain metastases typically includes radiotherapy (RT) with conventional fractionation and/or stereotactic radiosurgery (SRS). However, optimal indications and practice patterns for SRS remain unclear. We sought to evaluate national practice patterns for patients with metastatic disease receiving brain RT. Methods: We queried the National Cancer Data Base (NCDB) for patients diagnosed with metastatic non-small cell lung cancer, breast cancer, colorectal cancer, or melanoma from 2004 to 2014 who received upfront brain RT...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29209838/imp3-expression-in-nsclc-brain-metastases-demonstrates-its-role-as-a-prognostic-factor-in-non-neuroendocrine-phenotypes
#16
Alessandro Del Gobbo, Annamaria Morotti, Anna Eleonora Colombo, Valentina Vaira, Giulia Ercoli, Chiara Pesenti, Eleonora Bonaparte, Elena Guerini-Rocco, Andrea Di Cristofori, Marco Locatelli, Alessandro Palleschi, Stefano Ferrero
Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3...
December 1, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29185589/bevacizumab-and-gefitinib-enhanced-whole-brain-radiation-therapy-for-brain-metastases-due-to-non-small-cell-lung-cancer
#17
R F Yang, B Yu, R Q Zhang, X H Wang, C Li, P Wang, Y Zhang, B Han, X X Gao, L Zhang, Z M Jiang
Non-small-cell lung cancer (NSCLC) patients who experience brain metastases are usually associated with poor prognostic outcomes. This retrospective study proposed to assess whether bevacizumab or gefitinib can be used to improve the effectiveness of whole brain radiotherapy (WBRT) in managing patients with brain metastases. A total of 218 NSCLC patients with multiple brain metastases were retrospectively included in this study and were randomly allocated to bevacizumab-gefitinib-WBRT group (n=76), gefitinib-WBRT group (n=77) and WBRT group (n=75)...
November 17, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/29172778/response-to-afatinib-in-treatment-na%C3%A3-ve-patients-with-advanced-mutant-epidermal-growth-factor-receptor-lung-adenocarcinoma-with-brain-metastases
#18
COMPARATIVE STUDY
Shih-Hong Li, Chien-Ying Liu, Ping-Chih Hsu, Yueh-Fu Fang, Chun-Chieh Wang, Kuo-Chin Kao, Li-Chuan Tseng, Cheng-Ta Yang
BACKGROUND: Brain metastases are observable in 20-40% of non-small cell lung cancer patients, but standard treatments for such metastases may be intolerable to some. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were found to be effective against mutant-EGFR lung adenocarcinomas, but data regarding their effectiveness, especially for the second-generation EGFR-TKI afatinib, is limited. This study compared key outcomes for afatanib monotherapy versus afatinib combined with whole-brain radiotherapy (WBRT) in treatment-naïve lung adenocarcinoma patients harboring EGFR mutations...
January 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29142753/long-term-survival-in-a-patient-with-metastatic-squamous-cell-lung-carcinoma-a-case-report
#19
Emiddio Barletta, Piera Federico, Vincenza Tinessa, Domenico Germano, Lucia Cannella, Teresa Pironti, Bruno Daniele
Non-small-cell lung cancer (NSCLC) is the most common malignancy in industrialized countries, with a 5-year survival rate of only ~15%, as the majority of the patients have advanced-stage disease at diagnosis and the treatment options are limited. Squamous cell carcinoma the second most frequent type of NSCLC and is closely associated with cigarette smoking. We herein present the case of a 72-year-old male smoker, diagnosed with stage IV squamous cell lung carcinoma, with a solitary brain metastasis. After the diagnosis, stereotactic radiotherapy was performed on the brain metastasis...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29111173/epidermal-growth-factor-receptor-mutation-predicts-favorable-outcomes-in-non-small-cell-lung-cancer-patients-with-brain-metastases-treated-with-stereotactic-radiosurgery
#20
Wen-Chi Yang, Furen Xiao, Jin-Yuan Shih, Chao-Chi Ho, Ya-Fang Chen, Ham-Min Tseng, Kuan-Yu Chen, Wei-Yu Liao, Chong-Jen Yu, James Chih-Hsin Yang, Sung-Hsin Kuo, Jason Chia-Hsien Cheng, Pan-Chyr Yang, Feng-Ming Hsu
PURPOSE: The impact of epidermal growth factor receptor (EGFR) mutations on radiotherapy for brain metastases (BM) is undetermined. We evaluated the effects of EGFR mutation status on responses and outcomes in non-small cell lung cancer (NSCLC) patients with BM, treated with upfront or salvage stereotactic radiosurgery (SRS). METHODS AND MATERIALS: From 2008 to 2015, 147 eligible NSCLC patients with 300 lesions were retrospectively analyzed. Patterns of tyrosine kinase inhibitor (TKI) therapy were recorded...
October 27, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
42875
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"